Heart Failure
Conditions
Interventions
Specialized Oral Care
Standard Oral Care
Sponsors
Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have given their written consent to participate in this study 2. Patients aged 20 years or older at the time of consent 3. Patients hospitalized for worsening heart failure with symptoms of heart failure 4. NYHA classification 2-4 5. Patients who can be randomized within 7 days after this hospitalization 6. Patients who meet the following criteria for natriuretic peptide from 48 hours prior to this admission to the time of eligibility determination BNP over 200 pg/mL
Exclusion criteria
Exclusion criteria: 1. Patients with severe renal dysfunction (eGFR under 30 mL/min/1.73 m2), patients on maintenance dialysis, patients with known bilateral renal artery stenosis (known renal artery stenosis in the remaining kidney in patients with one kidney) 2. Patients with severe hepatic dysfunction (Child-Pugh classification C) 3. Patients with cardiogenic shock 4. Patients on cardiopulmonary assist devices, left ventricular assist ventricular assist devices, or ventilators 5. Patients with acute coronary syndrome or stroke within 30 days prior to randomization 6. Patients with a history of surgical or percutaneous treatment for cardiovascular disease within 30 days of randomization. 7. Patients with a preplanned coronary reconstruction or surgical or percutaneous treatment for cardiovascular disease during the individual observation period. 8. Patients with a preplanned treatment such as electrical cardioversion, cardiac resynchronization therapy or pacemaker implantation during the individual observation period. 9. Patients with obstructive hypertrophic cardiomyopathy or a history of or concomitant infiltrative cardiomyopathy such as amyloidosis or sarcoidosis 10. Patients with active pericardial disease 11. Patients with a history of dental visits to other hospitals within 3 months or currently undergoing dental treatment for dental caries, etc. 12. Patients with a history of or on the waiting list for a heart transplant 13. Patients with active infectious diseases or serious chronic respiratory diseases 14. Pregnant, potentially pregnant, or lactating patients 15. Other patients deemed inappropriate for this study by the principal investigator or subinvestigators (e.g., patients with active malignancies)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to onset of heart failure event or cardiovascular death | — |
Countries
Japan
Contacts
Public ContactKazuki Shiina
Tokyo Medical University Department of Cardiology
Outcome results
None listed